C

Cellivery Therapeutics Inc
KOSDAQ:268600

Watchlist Manager
Cellivery Therapeutics Inc
KOSDAQ:268600
Watchlist
Price: 6 680 KRW -29.91% Market Closed
Market Cap: 245B KRW
Have any thoughts about
Cellivery Therapeutics Inc?
Write Note

Cellivery Therapeutics Inc
Cash Taxes Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cellivery Therapeutics Inc
Cash Taxes Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Taxes Paid CAGR 3Y CAGR 5Y CAGR 10Y
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Cash Taxes Paid
-â‚©2.5m
CAGR 3-Years
19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Cash Taxes Paid
â‚©313.2B
CAGR 3-Years
79%
CAGR 5-Years
49%
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Cash Taxes Paid
â‚©763.6m
CAGR 3-Years
-3%
CAGR 5-Years
11%
CAGR 10-Years
N/A
S
ST Pharm Co Ltd
KOSDAQ:237690
Cash Taxes Paid
â‚©4.8B
CAGR 3-Years
N/A
CAGR 5-Years
78%
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Cash Taxes Paid
-â‚©35.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Cash Taxes Paid
â‚©877.7m
CAGR 3-Years
N/A
CAGR 5-Years
10%
CAGR 10-Years
35%
No Stocks Found

Cellivery Therapeutics Inc
Glance View

Market Cap
248.4B KRW
Industry
Life Sciences Tools & Services

Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmacy. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-11-09. The firm develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The firm research and develop therapeutic drug candidates such as Parkinson’s disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).

Intrinsic Value
1 694.23 KRW
Overvaluation 75%
Intrinsic Value
Price
C

See Also

What is Cellivery Therapeutics Inc's Cash Taxes Paid?
Cash Taxes Paid
-2.5m KRW

Based on the financial report for Sep 30, 2024, Cellivery Therapeutics Inc's Cash Taxes Paid amounts to -2.5m KRW.

What is Cellivery Therapeutics Inc's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 3Y
19%

Over the last year, the Cash Taxes Paid growth was 97%. The average annual Cash Taxes Paid growth rates for Cellivery Therapeutics Inc have been 19% over the past three years .

Back to Top